Lumpkin to industry: "You're a stakeholder, not a partner"
This article was originally published in RAJ Devices
Senior US Food and Drug Administration official Murray Lumpkin moved to distance the agency from the industries it regulates when he said earlier this week that the FDA “engaged” rather than collaborated with the pharmaceutical industry and that the industry was a "stakeholder" of the agency rather than a customer or even a partner.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib